A review of the mechanisms underlying selected comorbidities in Alzheimer's disease

Pharmacol Rep. 2021 Dec;73(6):1565-1581. doi: 10.1007/s43440-021-00293-5. Epub 2021 Jun 13.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) leading to mental deterioration and devastation, and eventually a fatal outcome. AD affects mostly the elderly. AD is frequently accompanied by hypercholesterolemia, hypertension, atherosclerosis, and diabetes mellitus, and these are significant risk factors of AD. Other conditions triggered by the progression of AD include psychosis, sleep disorders, epilepsy, and depression. One important comorbidity is Down's syndrome, which directly contributes to the severity and rapid progression of AD. The development of new therapeutic strategies for AD includes the repurposing of drugs currently used for the treatment of comorbidities. A better understanding of the influence of comorbidities on the pathogenesis of AD, and the medications used in its treatment, might allow better control of disease progression, and more effective pharmacotherapy.

Keywords: Alzheimer's disease; Comorbidities; Depression; Diabetes mellitus; Down syndrome; Hypercholesterolemia.

Publication types

  • Review

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / etiology
  • Alzheimer Disease / physiopathology
  • Animals
  • Disease Progression
  • Drug Development*
  • Drug Repositioning
  • Humans
  • Patient Acuity
  • Risk Factors